Sun制药公司计划投资100万美元,用于新推出的药物,目标是特殊市场的增长。 Sun Pharmaceutical plans $100M investment for new drug launches, targeting specialty market growth.

Sun制药工业计划在本财政年度投资1亿美元,以促进其特殊产品业务,重点是Unloxcyt和Leqselvi等新的药物发射活动。 Sun Pharmaceutical Industries plans to invest $100 million to boost its specialty products business in the current fiscal year, focusing on new drug launches like Unloxcyt and Leqselvi. 该公司的全球专业销售额增长了17.1%,在25财政年度达到12.16亿美元,今年的目标是实现中到高的一位数增长。 The company, which saw a 17.1% rise in global specialty sales to $1.216 billion in FY25, aims for mid-to-high single-digit growth this year. 26财政年度的研究与开发支出预计将占销售额的6%至8%。 Research and development spending for FY26 is expected to be 6-8% of sales.